Asymptomatic HIV-Infected Patients Present Blood Parameters Changed, According to Use of Therapy and the CD4+ T Cells Count
DOI:
https://doi.org/10.1590/s2175-97902022e20808Keywords:
HIV/AIDS, Antiretroviral therapy, Metabolic dysfunctions, Biochemical exams, Hematological exams, Metabolic alterationsAbstract
In HIV-patients, the imbalance in immunological, hematological and biochemical factors can contribute to the progression to AIDS and non-AIDS comorbidities, even during combined antiretroviral therapy (cART). In this cross-sectional study, we aimed to analyze some of these parameters in 138 different asymptomatic HIV-infected patients, doing multiple comparisons between the groups, which are dichotomized in the presence / absence of cART and type of immune response (immunological responders [iR,>500cells/mL] or non-responders [iNR,<500cells/ mL]). Were analyzed cytokines and other routine laboratory parameters. Our results showed high creatine phosphokinase and low IL-10 levels in cART-patients. They also presented metabolic alterations, including elevations in total cholesterol and triglycerides, particularly in those iNR. In ART-iR an increased alanine aminotransferase was observed. Those NAÏVE-iNR presented high LDL-cholesterol, C-reactive protein and lactate dehydrogenase values. The long-term non-progressors (LTNP) showed the best laboratory results. In conclusion, many blood parameters were changed in HIV-patients, especially in those under cART. To identify LTNP individuals could be important to discussions their early therapeutic onset.
Downloads
References
Atta MG: Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17(1):52-58.
Aukrust P, Muller F, Lien E, Nordoy I, Liabakk NB, Kvale D. Tumor necrosis factor (TNF) system in HIV-infected patients during highly active antiretroviral therapy (HAART)-persistent TNF activation is associated with virologic and imunologic treatment failure. J Infect Dis. 1999;179(1):74-82.
Brazille P, Dereuddre-Bosquet N, Leport C, Clayette P, Boyer O, Vildé JL, et al. Decreases in plasma TNFa level and IFNg mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients. Clin Exp Immunol. 2003;131(2):304-11.
DHHS. ART-Guidelines: Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2012. https://www.jwatch.org/ac201204020000001/2012/04/02/updated-dhhs-guidelines-hiv-treatment
» https://www.jwatch.org/ac201204020000001/2012/04/02/updated-dhhs-guidelines-hiv-treatment
Fahey JL. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol, 1998;5(5):597-603.
Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Annn Intern Med. 1996;124(7):654-63.
Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d’Arminio Monforte A, et al. For the DAD Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis . 2004;189(6):1056-74.
Geraix J, Carvalhaes MABL, Pereira PCM. Different nutritional-state indicators of HIV-positive individuals undergoing antiretroviral therapy. Venom Anim Toxins Incl Trop Dis. 2008;14(2):338-56.
Hadigan JB, Meigs C, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32(1)130-39.
Haissman JM, Lasse S, Vestergaard MD, Sembuche S. Plasma cytokine levels in tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr. 2009;52(4):493-97.
Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis . 2003;187(10):1534-43.
Krawczyk CM, Shen H, Pearce EJ. Memory CD4 T Cells Enhance Primary CD8 T-Cell Response. Infect Immun. 2007;75(7):3556-60.
Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11.
Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. AIDS. 2003;17(14):2035-44.
Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, Chilongola J. The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afri Health Sci. 2012;12(01):2-7.
Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8 T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3(11):1061-68.
Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, Loveless M, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood. 1996;87(3):919-25.
MS, Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS: Boletim epidemiológico - AIDS e DST. Ano IV. [http://www.aids.gov.br]. 2018.
Neto LFSP, das Neves MB, Ribeiro-Rodrigues R, Page K, Miranda AE. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz J Infect Dis . 2013;17(4):438-43.
Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis . 2010;201:1788-95.
Oliveira OCA, Oliveira RA, Souza LR. Impacto do tratamento antirretroviral na ocorrência de macrocitose em pacientes com HIV/AIDS do município de Maringá, Estado do Paraná. Rev Soc Bras Med Trop. 2011;44(01):35-9.
Palella FJ, Delaney KM, Mooreman AC, Loveless NO, Fuhrer J. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-60.
Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. N Engl J Med . 1995;332(4):209-16.
Parinitha SS, Kulkarni MH. Haematological changes in HIV infection with correlation to CD4 cell count. Aust Med J. 2012;5(3):157-62.
Pillaye JN, Marakalala MJ, Khumalo N, Spearman W, Ndlovu H. Mechanistic insights into antiretroviral drug-induced liver injury. Pharmacol Res Perspect. 2020;8(4):e00598.
Price P, Keane NM, Lee S, Lim AFY, McKinnon EJ, French MA. A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy. Immunology. 2006;119(1):74-82.
Souza SJ, Luzia LA, Santos SS, Rondó PH. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras. 2013;59(2):186-98.
Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83(8):3719-33.
Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis . 2010;202(Suppl 2):S302-S308.
Stylianou E, Aukrust P, Kvale D, Müller F, Frøland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol . 1999;116(1):115-20.
Tasca KI, Calvi SA, Souza LR. Immunovirological parameters and cytokines in HIV infection. Rev Soc Bras Med Trop . 2012;45(6)663-69.
Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS -defining morbid events during suppressive antiretroviral treatment. J Infect Dis . 2014;210(8):1248-59.
Venkataramana K. A study of biological markers in HIV disease progression and management in the highly active antiretroviral therapy (HAART) era. Am J Biosc Bioeng. 2013;1(2):24-37.
Viana GMC, Brandão MDS, Ferreira AM, Rabelo EMF, Diniz Neto JÁ, Galvão CS, et al. Evaluation of laboratory markers of progression of HIV disease to death. Rev Soc Bras Med Trop . 2011;44(6):657-60. https://pubmed.ncbi.nlm. nih.gov/22234355/
» https://pubmed.ncbi.nlm. nih.gov/22234355/
Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS . 2015;29(4):463-71.
WHO: Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic update. 2009.
Zaunders J, Bockel D. Innate and adaptive immunity in long-term non-progression in HIV disease. Front Immunol. 2013;4:95.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
